Defective genes account for∼ 80% of the total of more than 7,000 diseases known to date.
Gene therapy brings the promise of a one-time treatment option that will fix the errors in …

While clinical gene therapy celebrates its first successes, with several products already
approved for clinical use and several hundreds in the final stages of the clinical approval …

Bioengineering of viral vectors for therapeutic gene delivery is a pivotal strategy to reduce
doses, facilitate manufacturing, and improve efficacy and patient safety. Here, we …

Recombinant adeno-associated viruses (AAV) are under intensive investigation in
numerous clinical trials after they have emerged as a highly promising vector for human …

Adeno-associated virus (AAV) forms the basis for several commercial gene therapy products
and for countless gene transfer vectors derived from natural or synthetic viral isolates that …

Recombinant adeno-associated virus (rAAV) gene therapy has the potential to transform the
lives of patients with certain genetic disorders by increasing or restoring function to affected …

Sarcopenia is a comprehensive degenerative disease with the progressive loss of skeletal
muscle mass with age, accompanied by the loss of muscle strength and muscle dysfunction …

Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery
systems in gene therapy for inherited monogenetic diseases. First market approvals …

Adeno-associated viral (AAV) vector-mediated gene therapy holds great potential for future
medical applications. However, to facilitate safer and broader applicability and to enable …

Peripheral artery disease (PAD) is a vascular disorder caused by occlusive atherosclerosis,
which commonly impairs blood flow to the lower extremities. The prevalence of PAD is …